CC
SYRS

Casdin Capital’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Casdin Capital’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-27,407
Closed -$2.67M – 35
2017
Q4 		$2.67M Buy
27,407
+1,785
+7% +$240K 0.65% 23
2017
Q3 		$3.77M Buy
25,622
+7,408
+41% +$1.39M 1.06% 22
2017
Q2 		$2.93M Hold
18,214
– – 1.17% 25
2017
Q1 		$2.9M Hold
18,214
– – 1.71% 22
2016
Q4 		$2.21M Buy
18,214
+13,214
+264% +$1.85M 1.83% 20
2016
Q3 		$694K Hold
5,000
– – 0.56% 26
2016
Q2 		$908K Buy
+5,000
New +$908K 0.95% 26

Other funds holding SYRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.47T AUM 27.86% 1-Year Est. Return